
Treatment with nivolumab demonstrated clinical efficacy and safety in patients with platinum-resistant, recurrent, or advanced ovarian cancer.

Treatment with nivolumab demonstrated clinical efficacy and safety in patients with platinum-resistant, recurrent, or advanced ovarian cancer.

When bevacizumab (Avastin) was added to adjuvant chemotherapy, overall survival (OS) did not improve in patients with surgically resected early-stage non-small cell lung cancer (NSCLC)